La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Gencurix Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Sung-Rai Cho

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Nessun aggiornamento

Recent updates

Gencurix (KOSDAQ:229000) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 28

AMMINISTRATORE DELEGATO

Sung-Rai Cho

no data

Mandato

Sung-Rai Cho serves as Chief Executive Officer of Gencurix Inc.

Gencurix Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Recent updates

Second quarter 2024 earnings released: ₩281 loss per share (vs ₩506 loss in 2Q 2023)

New minor risk - Share price stability

Gencurix Inc. announced that it has received KRW 2 billion in funding

New major risk - Financial position

J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion.

J&L Agent Co., Ltd. and other agreed to acquire 9.9% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 5.9 million.

Full year 2023 earnings released: ₩1,629 loss per share (vs ₩2,989 loss in FY 2022)

Gencurix Inc. announced that it has received KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.

Gencurix Inc. announced that it expects to receive KRW 3.99999552 billion in funding from HLB PANAGENE Co., LTD.

Gencurix Inc. announced that it expects to receive KRW 3.99999552 billion in funding

Gencurix Inc. Obtains Approval for Companion Diagnostic of Digital Pcr-Based Egfr Mutation Test

Gencurix Announces Korean and Japanese Cancer Patients' 15-Year Follow-Up Prognostic Test Clinical Results

Investor sentiment improved over the past week

Gencurix Inc. announced that it has received KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

Gencurix Inc. announced that it expects to receive KRW 26.9999819 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, Aju IB Investment Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm and other investors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gencurix (KOSDAQ:229000) Is Posting Healthy Earnings, But It Is Not All Good News

New 90-day high: ₩21,700

New 90-day high: ₩21,000

New 90-day low: ₩16,950

Gencurix Inc. announced that it has received KRW 2 billion in funding

Gencurix Inc. (KOSDAQ:A229000) agreed to acquire a 41% stake in Nano Bio Life Co., Ltd. from Soo-kyung Kim, Jihye Cheon, Injoong Kim, Ki-moon Song, Jichul Hyun and Sujin Lee for KRW 3.7 billion.

New 90-day high - ₩26,750

New 90-day low - ₩15,700

AMMINISTRATORE DELEGATO

Mandato